Trials / Unknown
UnknownNCT05227846
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
A Phase 1 Dose Escalation Study of Human Umbilical Cord-derived Mesenchymal Stem Cells for the Treatment of Decompensated Cirrhosis (MSC-DLC-1)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Beijing 302 Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1, open label, dose escalation clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis. The purpose of this study is to assess the safety of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.
Detailed description
The primary objective of this study is to assess the safety of intravenous infusion of human umbilical cord-derived mesenchymal stem cells in patients with decompensated cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Human Umbilical Cord-derived Mesenchymal Stem Cells | Human Umbilical Cord-derived Mesenchymal Stem Cells will be administered intravenously. |
Timeline
- Start date
- 2022-03-22
- Primary completion
- 2024-06-30
- Completion
- 2025-03-01
- First posted
- 2022-02-07
- Last updated
- 2023-04-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05227846. Inclusion in this directory is not an endorsement.